A single-dose in vivo efficacy study showed significant tumor regression and prolonged survival in human PSMA-positive prostate cancer xenograft models after treatment with 212Pb-ADVC001, with some animals exhibiting a long-term survival benefit. This evidence concerns the gene FOLH1 and neoplasm.